Hemab Therapeutics Holdings, INC

Hemab Therapeutics Holdings, Inc. announced the election of Keli Walbert to its Board of Directors and Audit Committee, effective September 24, 2026.

Hemab Therapeutics announced strong Q2 2026 results with significant pipeline progress, including new data for HMB-002 and HMB-003, and advancement of sutacimig towards Phase 3 trials, bolstered by a substantial cash position post-IPO.

Hemab Therapeutics Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in R&D, progress in clinical trials for sutacimig and HMB-002, and a substantial cash position post-IPO.

Keli Walbert, a Director of Hemab Therapeutics Holdings, Inc., received 36,000 shares of common stock on September 24, 2026.

Novo Holdings A/S has reported beneficial ownership of 9.0% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh have collectively reported beneficial ownership of 7.06% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Capital International Investors has disclosed beneficial ownership of 3,603,876 shares, representing 7.7% of Hemab Therapeutics Holdings, Inc.'s common stock.

Several entities affiliated with Invus Group and Raymond Debbane have reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock, collectively holding 5.1% of the outstanding shares.

Sofinnova Crossover II SLP and associated entities have reported beneficial ownership of 5.4% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.